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Ka Yu Yeung1,2, Adam Dickinson1,2, Jacqueline F Donoghue3, Galina Polekhina5, Stefan J White6,
Dimitris K Grammatopoulos2,7, Matthew McKenzie4, Terrance G Johns3 and Justin C St John1*Abstract
Background: Mitochondrial DNA (mtDNA) encodes key proteins of the electron transfer chain (ETC), which
produces ATP through oxidative phosphorylation (OXPHOS) and is essential for cells to perform specialised
functions. Tumor-initiating cells use aerobic glycolysis, a combination of glycolysis and low levels of OXPHOS, to
promote rapid cell proliferation and tumor growth. Glioblastoma multiforme (GBM) is an aggressively malignant
brain tumor and mitochondria have been proposed to play a vital role in GBM tumorigenesis.
Results: Using next generation sequencing and high resolution melt analysis, we identified a large number of mtDNA
variants within coding and non-coding regions of GBM cell lines and predicted their disease-causing potential through
in silico modeling. The frequency of variants was greatest in the D-loop and origin of light strand replication in
non-coding regions. ND6 was the most susceptible coding gene to mutation whilst ND4 had the highest frequency of
mutation. Both genes encode subunits of complex I of the ETC. These variants were not detected in unaffected brain
samples and many have not been previously reported. Depletion of HSR-GBM1 cells to varying degrees of their mtDNA
followed by transplantation into immunedeficient mice resulted in the repopulation of the same variants during
tumorigenesis. Likewise, de novo variants identified in other GBM cell lines were also incorporated. Nevertheless, ND4
and ND6 were still the most affected genes. We confirmed the presence of these variants in high grade gliomas.
Conclusions: These novel variants contribute to GBM by rendering the ETC. partially dysfunctional. This restricts
metabolism to anaerobic glycolysis and promotes cell proliferation.
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phosphorylationBackground
Mitochondrial DNA (mtDNA) resides exclusively within
the matrix of the mitochondrion [1]. MtDNA is ~16.6 kb
in size and encodes 13 proteins that are essential to the
electron transfer chain, which produces the vast majority
of cellular ATP through the biochemical process of oxida-
tive phosphorylation (OXPHOS) [2]. It also consists of 22
tRNAs and 2 rRNAs and the D-Loop, which is the site of
interaction for the nuclear-encoded factors that regulate
mtDNA transcription and replication. The D-loop also
contains two hypervariable regions, which are indicative
of maternal ancestry [3].* Correspondence: justin.stjohn@monash.edu
1Mitochondrial Genetics Group, Centre for Genetic Diseases, Monash Institute
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stated.The absence of intronic regions increases the likelihood
of a variant residing within the coding regions of mtDNA
[4], especially since the non-coding region accounts for
only ~38% of the entire mitochondrial genome [5]. In the
disease state, mutations are commonly observed through-
out the mitochondrial genome [6,7]. Due to the presence
of multiple copies of mtDNA in the matrix of each mito-
chondrion and cells having large numbers of mitochondria,
mutant and wild-type mtDNA can co-exist.
Primarily, aerobic glycolysis is central to tumor cell
metabolism, as these cells exhibit three-times higher
glycolytic activity than their normal counterparts [8].
This reflects the Warburg effect, whereby cancer cells
undergo a metabolic transition, regardless of the oxygen
concentration available [9]. This causes the cell to favour
glycolysis rather than OXPHOS, as glycolysis generates
ATP at a higher rate than OXPHOS, which producesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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cellular proliferation and growth. It is therefore likely
that the presence of multiple mtDNA variants in a single
cell or cohort of cells would promote tumorigenesis as
there would be a decreased ability to generate ATP
through OXPHOS and an increased reliance on glycolysis.
Generally, there is an accumulation in the number of
mtDNA variants before a cell experiences detrimental
or phenotypic effects [11] and this is likely to be the case
for tumor cells. Nevertheless, it remains to be deter-
mined whether mtDNA variants present in tumors arise
from the clonal expansion of existing variants or if they
occur de novo. Normally, variants must be present at sig-
nificant levels to allow for their detection [12]. However,
next generation sequencing enables whole mitochondrial
genomes to be sequenced at a high coverage of over
1000-fold, which provides sufficient depth to identify
sequence variants at even low levels [13,14].
Although the benefits of using such technology are
clear, variants can be called that are interpreted as being
true variants but are erroneous [15]. High resolution
melt (HRM) analysis is an appropriate validation method
to confirm next generation sequencing results by elimin-
ating any errors that may have arisen from the sequen-
cing reactions [16] or from long PCR amplification [17].
Confirmed variants can then be analysed by bioinformat-
ics programs, such as SNPs & GO and MutPred that
predict the impact of the SNPs on protein function [18].
Gliomas account for 80% of all primary malignant
brain tumors and about 50% of gliomas give rise to Glio-
blastoma Multiforme (GBM) [19]. GBM has been rated
most severe (level 4) on the World Health Organisation’s
(WHO) scale of severity, due to its malignant nature
[20]. For patients diagnosed with GBM, prognosis is
poor with median survival estimated at 12–14 months
[21]. Indeed, only about 3-5% of patients survive beyond
3 years [21].
A number of cell lines are representative of GBM.
These include the frequently investigated lines, such as
U87MG, SF-767 [22] and HSR-GBM1 [23]. Within pa-
tient GBM tissues, amplification of epidermal growth
factor receptor (EGFR) genes is often observed [24]. This
is evident in the GBM 6 and HK301 neurosphere cell
lines, both of which express EGFRvIII. Others have been
established from expanded cultures from high-grade
human GBM tumors.
We have analysed a series of GBM cell lines using a
combination of next generation sequencing and HRM
analysis to identify variants within the mitochondrial gen-
ome that are indicative of tumorigenesis in GBM. We
have then depleted one of the cell lines to varying degrees
to determine whether the same variants reoccur following
mtDNA replenishment as tumorigenesis progresses. We
have applied several bioinformatic approaches to predictthe severity of each mutation and to model the effects on
protein structure. We have confirmed that these variants
are indicative of GBM through their identification in
GBM tumors. The frequency of variants is greatest within
the D-loop and the origin of light strand replication in the
non-coding regions whilst NADH dehydrogenase 6 (ND6)
is the most susceptible gene for the development of
mutations in the coding region.
Methods
Cell culture
The GBM cell lines GBM L1, GBM L2, GBM4, GBM6,
CSC020, CSC014, BAH-1 and HK301 were established
in-house directly from patient tumors using neural stem
cell conditions, as recently described by us [25]. None of
these cell lines was exposed to fetal calf serum (FCS).
HSR-GBM1, GBM L1, GBM L2 and hNSCs derived
from the NIH-approved H9 (WA09) human ESC line
(Invitrogen, Carlsbad, CA, USA) were cultured as neuro-
spheres on ultra-low attachment plates (Sigma, St. Louis,
MO) in DMEM/F12 Media containing 2% StemPro neural
supplement (both Gibco, Carlsbad, CA, USA), 20 ng/ml
basic fibroblast growth factor (bFGF) and 20 ng/ml epi-
dermal growth factor (EGF; both Millipore, Billerica, MA).
They were passaged every 3 days to maintain their undif-
ferentiated states. The GBM4, GBM6, CSC020, CSC014,
BAH-1 and HK301 cell lines were cultured in the same
manner but with knockout DMEM/F12 media and with
the addition of GlutaMAX (2 mM) only for the GBM 4,
CSC-020 and CSC-014 cell lines. The NO7-152 cell line is
an in-house cell line and is an early passage line grown in
the traditional manner using DMEM high glucose, 4%
non-essential amino acids (NEAA), 20% FCS and 2 mM
GlutaMAX (all from Gibco, Carlsbad, CA, USA). Both
U87MG (sourced directly from ATCC) and SF-767
(sourced directly from Brain Tumor Research Center
Tissue Core, UCSF) adherent cell lines were cultured in
DMEM/F12 Media supplemented with 5% FCS. Cells
underwent enzymatic passaging every 3 days using TrypLE™
Express (Gibco) to dissociate cells into a single cell
suspension.
MtDNA depletion
HSR-GBM1 cells were cultured as described above but in
the presence of the mtDNA depletion agent, 2′3′-dide-
oxycytidine (ddC), which was added daily during half
media changes at a concentration of 10 μg/ml, alongside
50 μg/ml of uridine (both: Sigma, St Louis, MO). Cells
were passaged every 3 days. They were allowed to recover
in vitro by withdrawal of ddC from the culture media.
Normal brain and tumor tissue samples
Normal human brain and tumor tissue samples were
obtained from the Victorian Brain Bank Network under the
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HREC. The normal human tissues were obtained from
individuals with no known history of neoplastic or neuro-
logical pathology. The brain tumor samples were from
patients diagnosed with high grade glioma.
Xenograft tumor models
Mouse experiments were approved by the Animal
Ethics Committee, Monash University, Approval Number:
MMCA/2011/76. HSR-GBM1 cells were depleted of their
mtDNA over 50 days in culture. They were harvested
after depletion to 50%, 20%, 3% and 0.2% of their
original mtDNA content. Following depletion, 5 × 105 cells
were resuspended in 100μl of Complete DMEM/StemPro
Media and inoculated subcutaneously into both leg regions
of immunedeficient female BALB/c nude mice (Animal
Research Centre, Perth, Australia) aged between 4 to 6 weeks
old. Tumors were extracted and stored at −80°C.
DNA extraction
DNA was extracted from cell pellets and tumors using the
DNeasy Blood & Tissue kit in the presence of RNase A
(Qiagen, West Sussex, UK), following the manufacturer’s
recommendations.
Long PCR
Templates for next generation sequencing were generated
by long PCR amplification of two overlapping fragments
that each spans half of the mitochondrial genome. 50 ng
DNA template was used per reaction, together with 1× High
Fidelity PCR buffer, 100 mM MgSO4, 1 mM dNTPs
(Bioline, London, UK), 1U of Platinum Taq High Fidelity
(Invitrogen, Carlsbad, CA, USA) in the presence of 10 μM
each of the forward and reverse primers (long1 F: 5′-GAC
GGGCTCACATCACCCCATAA-3′; long1 R: 5′-GCGTAC
GGCCAGGGCTATTGGT-3′; long2 F: 5′-GCCACAACTA
ACCTCCTCGGACTCCT-3′; long2 R: 5′-GGTGGCTGGC
ACGAAATTGACC-3′). All reactions were performed in a
total volume of 50μl. Conditions were 94°C for 2 minutes,
35 cycles of 94°C for 15 seconds, 63°C for 30 seconds and
68°C for 8 minutes 45 seconds. Products were purified using
the QIAquick PCR purification kit (Qiagen).
Next generation sequencing using the Ion Torrent Personal
Genome Machine (PGM)™
Purified amplicon pairs generated from long PCR were
combined at equal concentrations, prior to generation of
the amplicon libraries. Amplicon libraries were generated
using the recommended workflow procedures from the
Ion Fragment Library Kit and Ion Xpress™ Template kit
(Life Technologies). MtDNA was sheared using the Covaris
Adaptive Focused Acoustics™ system. Fragments of ap-
proximately 200 bp were selected following electrophoretic
separation with the E-gel system (Life Technologies).Confirmation of product and the quality of the mtDNA
was assessed by the Agilent Bioanalyzer using the Agilent
High Sensitivity DNA Kit (Agilent, Santa Clara, CA).
For multiplexing of the samples, each DNA library was
barcoded using different ligation adaptors. Libraries were
then pooled at equal concentrations and loaded onto 316
chips for sequencing. Sequence alignment to the reference
genome was performed using the Ion Torrent Suite (v.2.2).
Variant selection was performed using CLC Genomics
Workbench (v5.5.1). For quality control, reads were
filtered to exclude those of a nucleotide length of <15 bp,
with one nucleotide being trimmed from both ends of
each read. All reads accepted into analysis surpassed a
Phred quality score of 15. The following parameters were
applied to score reads during the selection process for
inclusion into the final alignment: setting a mismatch cost
of 2 and an insertion/deletion cost of 3; acceptance of
reads that had a minimum of 80% identity to the reference
sequence; and exclusion of all duplicate reads. For single
nucleotide polymorphism (SNP) analysis, a minimum
mutation threshold of 3% was applied.
HRM analysis
Genomic DNA samples for PCR were loaded on 96-well
plates (Bio-Rad Laboratories, Hercules, CA) with each
sample analysed in triplicate. The starting template for all
reactions was 10 ng in total, amplified in the presence
of 1× HRM master mix containing LCGreen® Plus +
(TrendBio), and 2.5 μM of forward and reverse primers
(Additional file 1: Table S1). Reactions were performed in a
total volume of 10 μl, with an overlay of 20 μl mineral oil
(Sigma). Amplification conditions were: 95°C for 2 minutes,
45 cycles of 94°C for 30 seconds and 55°C for 30 seconds,
followed by 1 cycle at 94°C for 30 seconds and cooling to
25°C for heteroduplex formation.
Products underwent melt analysis on the LightScanner
(Idaho Technologies, Salt Lake City, Utah) with analysis
performed using the LightScanner Instrument & Analysis
software with Call-IT 2.0 (V.2.0.0.1331). Data acquisition
began at 70°C and increased incrementally by 0.1°C until
the reaction terminated at 96°C [26].
Validation of next generation sequencing by HRM is
described in: Additional file 2: Supplementary Methods.
In silico predictive analysis on protein function
Web application tools SNPs & GO (University of Bologna)
and MutPred (v.1.2.) (Buck Institute, Indiana University)
were used to predict the potential effects of amino acid
changes to protein function. SNPs & GO uses the known
protein sequence, protein function and evolutionary data
based on the Swiss-Prot protein database to determine
whether the variant is ‘neutral’ or capable of causing
‘disease’, and provides a reliability value in association with
its prediction [27]. MutPred predicts the top five features
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amino acid substitution, and provides a probability value
for each prediction given [28].
Molecular protein modeling
Protein sequences were obtained from the National Center
for Biotechnology Institute database. The Clustal Omega
tool (EMBL-EBI) was used for sequence alignment. If a
protein structure shared a sequence identity of over 70% to
a protein of interest, the location of the mutation was
identified and its effect predicted using Swiss-PDB viewer
(v.4.1.0). Protein structures were obtained from the RCSB
Protein Data Bank (PDB) database (PDB ID for COX I:
1OCC_A, COX II: 1OCC_B, COX III: 1V54_C, CYT B:
1BGY_C, CYT C1: 1BGY_D, Rieske protein: 1BGY_E).
Results
Validation of the Ion Torrent PGM™ to detect a range of
sequence variants
PCR products containing a known mtDNA variant and its
wild-type counterpart were sub-cloned into DNA plasmids.
They were mixed at varying percentages to generate a series
of standard dilutions to test the sensitivity of the Ion Torrent
and were validated by HRM (Additional file 1: Table S1;
Additional file 3: Figure S1A-C).
Identification of variants in the GBM cell lines
The full mitochondrial genomes of 12 GBM cell lines were
then analysed by Ion Torrent to determine whether the
pattern of variants present are shared amongst all cell
lines. Altogether, 13 variants were detected in the non-
coding region (Table 1) and 19 in the coding region of the
mitochondrial genome (Table 2). Within the non-coding
region, the majority of variants occurred within the triple-
stranded D-loop region. The D-loop harbored the highest
frequency of mutation (77.9%) at position 16224 bp in the
U87MG cells. For GBM L1, GBM L2 and NO7-152 cell
lines, the occurrence of a variant at 310 bp of the D-loop
region was shared between the three lines at similar
frequencies whilst it was three-fold higher in the CSC014
cells. Variants at positions 2130 bp and 5752 bp were also
common, with 6 lines sharing the presence of both
variants at similar levels (GBM L1, GBM L2, GBM 4,
CSC014, CSC020 and NO7-152). Likewise, the GBM 6,
SF-767, U87MG, HK301 and BAH1 lines shared the
presence of the 16519 bp variant at high levels (range 51.2
to 58.2%), whilst the GBM 6 and U87MG cell lines shared
the presence of the 3168 bp variant (16 s rRNA) at a fre-
quency of 3.7%. For some shared variants, the frequency
differed considerably between lines. For example, the
D-loop variant at 302 bp was present in the GBM L1 cells
at 16.4%, approximately two-fold lower than for NO7-152
(at 39.9%) and CSC014 (at 41.5%) cells.For the 19 variants identified within the coding region of
the mitochondrial genome (Table 2), the levels ranged from
3.1% at position 12101 bp in the NADH dehydrogenase 4
(ND4) gene in the CSC-014 cell line to 55.5% at position
8252 bp (Cytochrome C Oxidase II; COX II) in the GBM L1
cell line. The most frequently observed variants were at
positions 11512 bp (ND4) and 14160 bp (ND6), which were
present in 5/12 and 8/12 lines, respectively. 16 of the vari-
ants resulted in non-synonymous amino acid changes whilst
3 were synonymous. Of the 16 non-synonymous substitu-
tions, 5 were predicted by the in silico web-based tool,
SNPs & GO, to be disease causing (Table 2). The 13061 bp
variant was predicted by MutPred to cause impaired protein
function due to the substitution of a glutamine for a proline
at position 242 in the NADH dehydrogenase 5 (ND5) poly-
peptide chain (P = 0.035) resulting in the loss of glycosyla-
tion. The variant at position 14159 bp substituted a proline
for a methylated arginine at position 172, again disrupting
protein function (P = 0.03). The cytochrome B (CYT B)
disease-causing variants at positions 15264 bp and 15267 bp
were predicted to result in the loss of relative solvent
accessibility and gain of glycosylation, respectively.
Overall, the majority of variants in the coding regions for
all 12 cell lines arose in the ND4 region (n = 6 variants).
Both the ND5 and ND6 genes, the latter of which is
encoded on the light strand of mtDNA, possessed the
second highest number of variants (n = 3). The ND6 variant
at position 14160 bp was the most common mutational
event with 8/12 lines harboring this variant. All variants
were confirmed using HRM analysis, for example see
Additional file 4: Figure S2.The susceptibility of the different mtDNA gene regions to
the development of variants
To determine the susceptibility of various mtDNA
regions to mutation, we normalized the number of vari-
ants identified in each mtDNA region to the size of the
gene region (bp) on which the variant was located. The
overall probability of deriving a mutation in the non-
coding region (2.08 × 10-3) was greater than in the cod-
ing region (1.84 × 10-3) (Additional file 5: Table S2). The
12S rRNA region was found to be the least susceptible
to mutation of all the non-coding regions (n = 1 variant
within 953 bp: Additional file 5: Table S2) whilst the
origin of light strand replication (1 variant within 77 bp)
was the region most likely to develop mutation (12.38X
greater than for the 12S rRNA region) (Additional file 5:
Table S3). Although the D-loop harboured 7 variants,
due to its size, it was the second most susceptible non-
coding region to mutation. In the coding region, Cyto-
chrome C Oxidase I (COX I) was the least susceptible to
acquiring mutation (1.298 × 10-3), whilst ND6 was the
most susceptible (5.725 × 10-3), representing a 4.41X
Table 1 MtDNA variants identified from sequencing the non-coding region of mtDNA using the Ion Torrent PGM on 12 cell lines representative of GBM
Percentage change in variant (%)
Reference position Reference Variant HSR-GBM1 GBM L1 GBM L2 GBM 4 GBM 6 CSC 014 CSC 020 NO7 152 SF-767 U87MG HK301 BAH1 Gene region
16186 C C/T 4.5 D loop - Hypervariable
segment 1, 7S DNA, membrane
attachment site16218 C C/T 16.9
16224 T T/C 77.9
16519 T T/C 53.7 55.8 58.2 51.2 52.9 D loop - 7S DNA, membrane
attachment site
194 C T/C 4.1 D loop - Hypervariable segment 2,
membrane attachment site
302 A A/C 16.4 41.5 39.9
310 T T/C 5.6 5.0 17.5 6.0
1386 T T/C 9.9 12s rRNA
2002 G G/A 11.1 16s rRNA
2130 A A/G 3.9 5.5 4.0 3.6 6.3 7.4
2817 G G/A 11.7
3168 C C/T 3.7 3.7
5752 A A/G 11.3 13.1 11.4 10.5 10.9 9.9 L strand replication origin
Variants represent those that arise at a percentage frequency of or greater than 3%, after strict parameters were applied to exclude low quality reads from the final mapping of each full mitochondrial genome
sequence. Variants that have not been previously reported are in bold.
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Table 2 MtDNA variants identified within the coding region of 12 GBM cell lines
Percentage change in variant (%) MutPred
Reference
position
Variant
change
HSR-
GBM1
GBM
L1
GBM
L2
GBM
4
GBM
6
CSC
014
CSC
020
NO7
152
SF-
767
U87MG HK301 BAH1 Gene
region
Amino
acid
change
SNPs & GO Probability of
deleterious
mutation
Top 5 predicted
features caused by
the amino acid
mutation
6422 C→T 3.8 COX I Syn (P) - -
6999 G→A 6.5 V366M Neutral, RI 4,
uniprot
P00395
0.454 Loss of stability
(P = 0.0688)
Loss of sheet
(P = 0.0817)
Loss of catalytic
residue at V366
(P = 0.1011)
Loss of glycosylation
at S362 (P = 0.2022)
Gain of loop
(P = 0.4661)
8251 G→A 43.5 50.8 COX II Syn (G) - -
8252 C→A 55.5 46.8 P223T Neutral, RI 9,
uniprot
P00403
0.327 Gain of glycosylation
at P223 (P = 0.1135)
Loss of disorder
(P = 0.1694)
Loss of catalytic residue
at G222 (P = 0.2169)
Loss of phosphorylation
at T226 (P = 0.3735)
Loss of helix
(P = 0.3949)
10473 C→G 4.3 ND4L P2A Neutral, RI 9,
uniprot
P03901
0.344 Loss of disorder
(P = 0.0496)
Loss of catalytic
residue at L3
(P = 0.1395)
Gain of helix
(P = 0.2684)
Loss of loop
(P = 0.3664)
Loss of phosphorylation
at Y5 (P = 0.4053)
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Table 2 MtDNA variants identified within the coding region of 12 GBM cell lines (Continued)
10814 A→C 6.0 5.3 5.0 5.2 ND4 K19Q Neutral, RI 8,
uniprot
P03905
0.551 Loss of methylation
at K19 (P = 0.0012)
Loss of ubiquitination
at K19 (P = 0.0283)
Loss of MoRF binding
(P = 0.134)
Gain of helix
(P = 0.2684)
Loss of catalytic residue
at K19 (P = 0.2966)
11361 T→C 6.0 M201T Neutral, RI 5,
uniprot
P03905
0.706 Loss of stability
(P = 0.0853)
Gain of ubiquitination
at K206 (P = 0.1204)
Gain of catalytic residue
at M201 (P = 0.1253)
Gain of methylation
at K206 (P = 0.1903)
Loss of MoRF binding
(P = 0.2081)
11512 C→A 6.0 9.6 11.0 6.4 15.2 N251K Neutral, RI 4,
uniprot
P03905
0.495 Gain of methylation
at N251 (P = 0.0194)
Gain of MoRF binding
(P = 0.0632)
Loss of stability
(P = 0.0709)
Loss of ubiquitination
at K255 (P = 0.0768)
Gain of solvent accessibility
(P = 0.0837)
11674 C→T 3.5 Syn (T) - -
12101 T→C 3.8 3.1 4.2 S448P Neutral, RI 7,
uniprot
P03905
0.484 Loss of helix
(P = 0.0093)
Gain of loop
(P = 0.0321)
Gain of relative
solvent accessibility
(P = 0.09)
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Table 2 MtDNA variants identified within the coding region of 12 GBM cell lines (Continued)
Gain of sheet
(P = 0.1451)
Gain of catalytic residue
at L447 (P = 0.1502)
12102 C→T 3.7 3.2 S448F Neutral, RI 3,
uniprot
P03905
0.472 Loss of disorder
(P = 0.0619)
Gain of helix
(P = 0.2059)
Loss of loop
(P = 0.2897)
Loss of phosphorylation
at S448 (P = 0.5302)
Gain of catalytic residue
at S448 (P = 0.5425)
12877 G→C 27.7 ND5 G181R Disease, RI 7,
Uniprot
P03915
0.795 Loss of catalytic residue
at I183 (P = 0.1945)
Gain of MoRF binding
(P = 0.2553)
Gain of methylation
at G181 (P = 0.3559)
Loss of helix
(P = 0.4763)
Loss of stability
(P = 0.5598)
13043 C→T 3.3 A236V Neutral, RI 3,
Uniprot
P03915
0.786 Loss of glycosylation
at P234 (P = 0.0757)
Loss of disorder
(P = 0.0789)
Gain of helix
(P = 0.132)
Loss of phosphorylation
at T241 (P = 0.2504)
Loss of loop
(P = 0.2897)
13061 C→A 4.0 P242Q Disease, RI 0,
uniprot
P03915
0.776 Loss of glycosylation
at P242 (P = 0.035)
Loss of phosphorylation
at T241 (P = 0.1079)
Loss of disorder
(P = 0.1807)
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Table 2 MtDNA variants identified within the coding region of 12 GBM cell lines (Continued)
Loss of catalytic residue
at E238 (P = 0.1978)
Loss of helix
(P = 0.2271)
14159 C→G 4.1 ND6 R172P Disease, RI 3,
uniprot
P03923
0.423 Loss of methylation
at R172 (P = 0.0305)
Gain of catalytic residue
at R172 (P = 0.0632)
Loss of sheet
(P = 0.0817)
Loss of stability
(P = 0.126)
Gain of disorder
(P = 0.1619)
14160 G→C 4.0 3.5 3.3 7.5 4.3 3.2 8.1 5.0 R172G Neutral, RI 2,
uniprot
P03923
0.442 Loss of methylation
at R172 (P = 0.0305)
Loss of stability
(P = 0.0532)
Loss of sheet
(P = 0.0817)
Gain of disorder
(P = 0.1578)
Gain of loop
(P = 0.2045)
14426 C→T 8.9 G85E Neutral, RI 7,
uniprot
P03923
0.364 Loss of glycosylation
at S84 (P = 0.0357)
Gain of solvent accessibility
(P = 0.0456)
Loss of catalytic residue
at V86 (P = 0.1017)
Gain of disorder
(P = 0.1294)
Gain of loop
(P = 0.2045)
15264 C→T 14.1 CYTB P173L Disease, RI 4,
uniprot
P00156
0.361 Loss of relative
solvent accessibility
(P = 0.0793)
Loss of solvent
accessibility
(P = 0.089)
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Table 2 MtDNA variants identified within the coding region of 12 GBM cell lines (Continued)
Gain of methylation
at R177 (P = 0.1226)
Loss of glycosylation
at S172 (P = 0.1763)
Loss of disorder
(P = 0.2084)
15267 C→G 20.5 T174S Disease, RI 3,
uniprot
P00156
0.866 Gain of glycosylation
at T174 (P = 0.0587)
Gain of disorder
(P = 0.0665)
Loss of catalytic residue
at T174 (P = 0.1513)
Loss of methylation
at R177 (P = 0.2045)
Loss of sheet
(P = 0.3635)
In silico analysis was performed using the online tools SNPs & GO and MutPred to predict the impact these variants exert on the corresponding protein of interest. Variants that have not been previously reported are
in bold.
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Table S3).Protein modeling of non-synonymous amino acid
substitutions
To understand the impact of non-synonymous amino acid
changes induced by the introduction of variants into the
mitochondrial genome, we performed protein modeling
on the bovine protein structures for COX I, COX II and
CYT B equivalents due to the unavailability of the human
structures. These are 91%, 72% and 78.4% homologous to
their respective human proteins. The ND subunits do not
have protein structures available that closely resemble the
corresponding human protein sequence.Figure 1 Protein structure of the complex III catalytic centre (the cyto
in cytochrome B. (A) The catalytic centre of complex III is shown, represen
C1 (blue) and the Rieske iron-sulfur protein (green). The key redox cofactor
in cytochrome C1. Oxidation of ubihydroquinone (QH2) occurs at the Qo sit
these events, a membrane potential is generated across the inner mitocho
cytochrome B and C1 subunits. (B) Location of the proline to leucine (P173
cytochrome B. Both of these reside on a transmembrane helical region of t
T174S mutations.The CYT B variants at mtDNA nucleotide positions
15264 bp and 15267 bp induce a transition from proline
to leucine at position 173 (P173L) for the variant at
15264 bp, and a change from threonine to serine at
position 174 (T174S) for the 15267 bp variant. These
variants are located at the terminal end of one of the
transmembrane helical domains on CYT B (Figure 1).
However, their relatively central location in relation to
the catalytic centre of CYT B is predicted to impact on
function. The mtDNA variant identified at position
6999 bp in the COX I region of the HSR-GBM1 cells
induces a change from valine to methionine at position
366 of the polypeptide chain. However, the mutational
change resides within a transmembrane helix region that
faces towards the mitochondrial intermembrane spacechrome bc1 complex) with annotated locations for the variants
ted by three interacting subunits, cytochrome B (yellow), cytochrome
s are Heme bL and bH, which reside within cytochrome B, and heme c1
e, and reduction of ubiquinone to ubiquinol at the Qi site. Following
ndrial membrane. The Rieske iron-sulfur protein interconnects the
L) and threonine to serine (T174S) mutations are highlighted on
he subunit. (C) Magnified view of the adjacent P173L and
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neutral effect (Table 2). The variant at position 8252 bp
in COX II of the HSR-GBM1 cells results in a proline to
a threonine transition at position 223 (P223T) of the
protein sequence. It maps to a helix region located away
from the catalytic core of complex IV in the mitochon-
drial intermembrane space (Additional file 7: Figure S4)
and is thus predicted to be neutral (Table 2).
Variants identified in the brain tissue of normal brain
biopsy patients
In order to determine the type and frequency of mtDNA
variants in brain samples from unaffected individuals,
we analysed brain tissue samples from 13 individuals
with no known brain disease. The majority of variants
(14/21) were present in hypervariable regions I and II of
the D-loop (Table 3). Sample 05–470 possessed the
highest number of non-coding variants (n = 12) whilst
the remaining 12 samples possessed 5 or fewer. Apart
from the variant at position 16519 bp, the other variants
were present at frequencies <10% except for the A→G
substitution at position 16293 bp, which was present at
16.1% in 04–273, and the G→C substitution at 12.1% at
position 2647 bp in the 16 s rRNA region for sample
05–470.
In the coding region of the normal samples, 39 variants
were identified (Table 4). CYT B harboured the largest
proportion of variants (9/39) whilst ND4 possessed the
second highest proportion of variants (6/39). The majority
of variants (21/39) led to non-synonymous amino acid
changes, whilst 1 variant generated a stop codon at
position 8630 bp.
The D-loop region was the most susceptible to muta-
tion (1.517 × 10-2) amongst the coding and non-coding
regions of mtDNA with COX I being the least susceptible
(6.4893 × 10-4) (Additional file 5: Table S4) representing a
23.37-fold difference (Additional file 5: Table S5). Within
the coding region, CYT B was the most susceptible
amongst all other coding genes with a score 12.17X higher
than that for COX I (Additional file 5: Table S5).
Identification of variants through cell culture
In order to determine whether the culture environment
would induce mtDNA variants over time, we sequenced
the mitochondrial genome of a human neural stem cell
(hNSC) line that had been subjected to multiple passa-
ging (x20). We identified 2 variants in the non-coding
region, which were restricted to the D-loop region. The
variant at position 16519 bp had the highest percentage
change at 51.3% whilst the variant at position 496 was
present at 3.3%. In the coding region, there were 4 vari-
ants, namely three located in ND5 at positions 13762 bp
(3.2%), 13984 (3.6%) (D-loop) and 13985 (3.6%) and 1
residing in CYT B at position 15153 bp (9.4%). The lowlevel of percentage variant present reflects the low levels
identified in the normal samples. Furthermore, compari-
son of the variants present in the traditional immorta-
lised lines (NO7 152, SF-767 and U87MG) and the
primary glioma lines (GBM L1; GBM L2; GBM 4; GBM
6; CSC014; CSC020, HK301 and BAH1) did not reveal a
greater distribution of mtDNA variants for one set of
lines.
Phylogenetic analysis of the GBM cell lines and normal
brain samples
In order to determine that the normal samples and the
GBM cell lines were not indicative of tight cohorts of
mtDNA clusters but were from comparable lineages, we
subjected them to phylogenetic analysis. As can be seen
from Additional file 8: Figure S5, there is no bias due to
the equal distribution of samples across a wide mtDNA
genetic distribution and that the variants observed
appear to be unique to the tumor samples.
Identification of mtDNA variants essential to
tumorigenesis
In order to determine which mtDNA variants identified
in the GBM cell lines are essential to tumorigenesis, we
depleted HSR-GBM1 cells to varying degrees, namely to
50% (mtDNA50), 20% (mtDNA20), 3% (mtDNA3) and
0.2% (mtDNA0.2) of their original mtDNA content.
We transplanted these and non-depleted HSR-GBM1
(mtDNA100) cells into BALB/c nude mice and assessed
whether the same or other mtDNA variants were
selected for as cells replenished their mtDNA content
during tumorigenesis.
Through HRM, we determined that 10/22 of the tu-
mors harboured all of the variants present in the paren-
tal cells whilst 9 (2 mtDNA100, 5 mtDNA50, 1 mtDNA20
and 1 mtDNA0.2) shared 15/16 variants. Another 2 tu-
mors (1 mtDNA100 and 1 mtDNA3) shared 14/16 vari-
ants and 1 (mtDNA20) shared 13/16 variants (Figure 2).
In the non-coding region, the variants at 16186 bp,
16218 bp, 302 bp, 310 bp and 1386 bp (12 s rRNA)
persisted in all tumors, whereas the variants at 6999 bp
(COX I), 11361 bp and 11674 bp (ND4), 14159 bp and
14160 bp (ND6), and 15264 bp and 15267 bp (CYT B)
persisted in the coding region of all tumors.
Nevertheless, there was an overall gain in the number
of variants (Figure 3) as a function of cells having under-
gone increased levels of mtDNA depletion (P = 0.0027).
Specifically, there were significant differences in the in-
cremental gain of variants between the parental cells
and the mtDNA20 (P < 0.05), mtDNA3 (P < 0.01) and
mtDNA0.2-derived (P < 0.01) tumors (Figure 3). These
variants were identified in the other GBM cell lines. The
variants that were persistently selected were at 10473 bp
(NADH dehydrogenase 4L; ND4L), 10814 bp, 12101 bp
Table 3 Variants detected within the non-coding region of mtDNA in normal brain tissue (n = 13)
Percentage change in variant (%)
Reference position Reference Variant 03-965 04-273 05-470 07-104 07-445 07-635 08-012 08-026 09-005 09-152 16-1 22-1 20-1 Gene region
16069 C T 7.2 D loop - Membrane attachment site,
Hypervariable segment 1
16126 T C 5.2 D loop - Membrane attachment site,
Hypervariable segment 1, 7S DNA
16145 G A 4.8 D loop - Membrane attachment site,
Hypervariable segment 1, 7S DNA,
termination-associated sequence
16179 C T 4.3 D loop - Membrane attachment site,
Hypervariable segment 1, 7S DNA
16222 C T 5.1
16261 C T 9.4
16293 A G 16.1
16356 T C 3.0
16519 T C 57.5 54.5 56.0 57.6 58.3 59.4 D loop - Membrane attachment
site, 7S DNA
9 G T 5.8
10 T C 5.8
66 G T 3.2 D-loop - Hypervariable segment 2,
membrane attachment site, 7S DNA
73 A G 6.2
150 C T 4.4 D loop - Hypervariable segment 2,
H-strand origin, Membrane
attachment site, 7S DNA189 A G 3.0
195 T C 4.5 D loop - Hypervariable segment 2,
H-strand origin, Membrane
attachment site
242 C T 7.7 D loop - Hypervariable segment 2,
H-strand origin, mtTF1 binding site,
Membrane attachment site
751 A T 3.9 12s ribosomal RNA (rRNA)
2232 A T 3.0 16s ribosomal RNA (rRNA)
2647 G C 12.1
3010 G A 3.5
Variants represented those that were present at or above the 3% mutation threshold selection criteria. Variants that have not been previously reported are in bold.
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Table 4 Variants identified in the coding region of the mitochondrial genome in normal brain tissue samples
Percentage change in variant (%) MutPred
Reference
position
Reference Variant 03-
965
04-
273
05-
470
07-
104
07-
445
07-
635
08-
012
08-
026
09-
005
09-
152
16-1 22-1 20-1 Gene
region
Amino
acid
change
SNPs & GO Probability of
deleterious
mutation
Top 5 predicted
features caused by
amino acid mutation
4646 T C 3.4 ND2 Syn (Y) -
4701 A T 4.8 N78Y Neutral, RI 7,
Uniprot P03891
0.329
4703 T C 4.8 Syn (N) -
4878 G A 4.6 A137T Neutral, RI 5 0.786
4879 C G 5.0 A137G Neutral, RI 5 0.78 Loss of stability
(P = 0.0465)
6146 A G 3.1 COX I Syn (W) -
8497 A G 12.5 4.8 ATP8 Syn (M) -
8630 A G 3.7 ATP6 K35 Stop Uniprot P00846
8756 T C 6.5 I77T Neutral, RI 5 0.684 Loss of stability
(P = 0.0062)
8790 G A 18.4 Syn (L) -
8994 G A 4.7 Syn (L) -
9070 T G 6.2 S182A Neutral RI 5 0.162 Loss of glycosylation
at S182 (P = 0.0094)
9258 C T 3.2 COX III Syn (L) -
9526 C G 5.0 3.8 A107G Neutral, RI 5,
Uniprot P00414
0.667 Loss of stability
(P = 0.0332)
9528 C A 9.9 6.4 4.8 P108T Neutral, RI 2 0.731
9558 C A 5.8 3.6 P118T Disease, RI 3 0.579 Loss of catalytic residue
at P117 (P = 0.0195)
Gain of glycosylation
at P118 (P = 0.0283)
10398 A G 5.4 ND3 T114A Neutral,
RI 10, Uniprot
P03897
0.071
10993 G A 4.6 ND4 Syn (M) -
11332 C T 3.4 Syn (A) -
11467 A G 3.1 Syn (L) -
11516 C A 4.9 L253M Neutral, RI 7,
Uniprot P03905
0.369
11725 A T 3.0 Syn (T) -
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Table 4 Variants identified in the coding region of the mitochondrial genome in normal brain tissue samples (Continued)
11791 C T 11.8 Syn (L)
12719 T C 3.2 ND5 M128T Disease, RI 2,
Uniprot P03915
0.795 Loss of stability
(P = 0.0126)
12774 C T 9.3 Syn (G)
13984 C T 3.7 Syn (L) -
13985 T C 3.1 3.1 3.7 L550P Neutral, RI 1 0.457 Gain of loop
(P = 0.0013)
Loss of helix
(P = 0.0041)
Gain of catalytic
residue at P549
(P = 0.0244)
Gain of glycosylation
at L550 (P = 0.0364)
Gain of relative
solvent accessibility
(P = 0.0479)
14155 C T 3.8 ND6 Syn (G) -
14159 C G 12.5 R172P Disease, RI 3,
Uniprot P03923
0.423 Loss of methylation
at R172 (P = 0.0305)
14160 G C 8.1 12.5 R172G Neutral, RI 2 0.442 Loss of methylation
at R172 (P = 0.0305)
14770 C A 8.0 CYT B N8K Neutral RI 1,
Uniprot P00156
0.446 Gain of methylation
at N8 (P = 0.0039)
Gain of MoRF
binding (P = 0.0159)
Gain of ubiquitination
at N8 (P = 0.0452)
14823 A C 4.0 N26T Disease, RI 6 0.752
14857 T C 3.8 Syn (L) -
14861 G T 3.6 A39S Neutral, RI 5 0.33
14866 C T 5.4 Syn (C ) -
15287 T C 26.9 F181L Neutral, RI 3 0.617
15452 C A 3.2 L236I Neutral, RI 7 0.307
15579 A T 3.7 Y278F Disease, RI 6 0.796
15693 T C 4.9 M316T Neutral, RI 8 0.312
Variants represented those that were present at or above the 3% mutation threshold selection criteria. Variants that have not been previously reported are in bold. Predictions on the effects of amino acid
substitutions were performed using MutPred and SNPs & GO online tools.
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Figure 3 HSR-GBM1 cells and HSR-GBM1 cells depleted of their
mtDNA to levels of 50%, 20%, 3% and 0.2% of their original
mtDNA copy number were transplanted into immunedeficient
nude mice and developed as tumors with mtDNA copy number
being replenished in vivo. The number of variants gained relative
to the non-depleted HSR-GBM1 cells was assessed using HRM.
*P = <0.05, **P = <0.01.
Cell line Control tumor samples MtDNA depleted mice tumor samples
Reference 
Position
Variant
change Gene region
HSR-
GBM1 mtDNA
100 mtDNA50 mtDNA20 mtDNA3 mtDNA0.2
N
o
n
-c
o
di
ng
 
re
gi
o
n
16186 C T
D-loop
16218 C T
194 C T
302 A C
310 T C
1386 T C 12s rRNA
2130 A G 16s rRNA
5752 A G Origin of L-strand replication
Co
di
n
g 
re
gi
o
n
6422 C T Cytochrome C Oxidase I6999 G A
8251 G A Cytochrome C Oxidase II8252 C A
10473 C G NADH dehydrogenase 4L
10814 A C
NADH dehydrogenase 4
11361 T C
11512 C A
11674 C T
12101 T C
12102 C T
13061 C A NADH dehydrogenase 5
14159 C G
NADH dehydrogenase 614160 G C
14426 C T
15264 C T Cytochrome B15267 C G
Similarity to HSR-GBM1 (%) - 93.8 87.5 93.8 100 100 93.8 93.8 93.8 93.8 93.8 100 100 100 93.8 81.3 100 87.5 100 100 100 93.8 100
Gain in variants to HSR-GBM1 - 1 3 6 1 4 7 2 1 4 5 4 6 7 4 6 10 8 6 7 4 6 9
Variant absent (sites jointly analysed)Variant present (sites jointly analysed)Variant absentVariant present
Figure 2 HRM analysis of HSR-GBM1 cells that have undergone mtDNA depletion for up to 50 days, followed by the replenishment of
mtDNA in vivo in immunedeficient nude mice, based on the panel of variants identified across the different GBM cell lines. Tumors
mtDNA50, mtDNA20, mtDNA3 and mtDNA0.2 were generated with HSR-GBM1 cells depleted of their mtDNA copy number to 50%, 20%, 3% and
0.2% of their original copy number relative to non-depleted HSR-GBM1 cells (mtDNA100). Multiple samples for each tumor type represent
experimental replicates. The variants highlighted in yellow indicate variants shared between all samples analysed. Variants highlighted in orange
represent those that have been acquired de novo during tumor formation and were identified within the other GBM cell lines.
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(ND6). Interestingly, the variants associated with the
ND4 and ND5 were more frequently present in the
mtDNA20-derived, mtDNA3-derived and mtDNA0.2-de-
rived tumors, as was the ND6 tumor-specific variant at
14426 bp (Figure 2). We then assessed the presence of
variants in cells depleted to 50%, 20% and 3% of their
original mtDNA content and then allowed to recover in
culture over 14 days. As can be seen from Additional file
5: Table S6, the vast majority of the variants are present
in recovered cells, although those variants at 10473 bp
(ND4L), 10814 bp, 12101 bp and 12102 bp (ND4) and
13061 bp (ND5) were less frequently present. This sug-
gests that a specific set of mtDNA variants are required
to initiate GBM tumorigenesis and that they are selected
for whilst those not essential to tumorigenesis appear to
be selected against.
Identification of the tumor-specifying variants in
patient samples
In order to determine whether the variants identified in
our in vivo tumorigenesis model are present in GBM
patient samples, we screened high grade tumors obtained
from 22 patients diagnosed with glioma (Additional file 5:
Table S7). Each of the variants was present in the majority
of patient tumor samples with tumor sample T16 sharing
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(COX I), 8251 bp, 8252 bp (both COX II) and 11361 bp
(ND4) were present in all patient tumors whilst the
variants at 6999 bp and 11361 bp were also common to
all tumors derived from our in vivo model.
Discussion
This is the first study using next generation sequencing
to identify the presence of mtDNA variants in GBM cell
lines, which are representative of the relapse and/or re-
fractory stage of the disease. We used a two-fold strategy
to ensure that the variants identified were present within
the cells and were not artifacts. Firstly, we amplified the
two overlapping regions of the mitochondrial genome by
long PCR followed by next generation sequencing, an
approach used by others to, for example, identify the de-
gree of heteroplasmy amongst different populations [29].
Importantly, this strategy ensured that we were not screen-
ing and, thus identifying variants, in nuclear pseudo-genes
but rather targeting the mitochondrial genome itself [30].
Indeed, isolation of mitochondria and subsequent extrac-
tion of mtDNA can result in DNA samples possessing
contaminating nuclear DNA. Secondly, we validated the
presence of the variants using HRM on genomic DNA,
which enabled us to confirm that the variants were ‘true’
calls, and not introduced during long PCR.
Overall, the GBM cell lines harbored proportionally
more previously reported variants (16/29) than the nor-
mal, unaffected brain samples (20/60) following searches
on the MitoMap variant database. Specifically, for the
GBM cell lines, 4/13 variants that have not been previ-
ously reported resided within the non-coding region and
12/19 within the coding region. For the normal samples,
there were two previously unidentified variants in the
non-coding region and 18 in the coding region. Indeed,
it was most apparent that there were only three variants
common to the GBM cell lines and the normal samples,
one in the D-loop at position 16519 bp (D-loop) and
two in the coding genes at positions 14159 bp and
14160 bp (ND6). The 16519 bp variant has been identi-
fied in multiple studies [31] and was present in both
cohorts at similar levels. However, the 14159 bp and
14160 bp variants have not been previously reported.
Consequently, it appears that two distinct populations of
variants define the two cohorts.
Although the variants identified in the GBM and nor-
mal cohorts appear to be randomly distributed through-
out the mitochondrial genome, certain regions were
not affected. No variants were identified in the NADH
dehydrogenase 1 (ND1) gene or the 22 tRNAs suggesting
that the incorporation of variants was highly selective to
the other 12 coding genes and the D-loop region. More-
over, different regions of the mitochondrial genome were
more susceptible to mutation in the normal samplesthan the GBM cell lines. For the GBM cells, ND6 and
ND4 were the most susceptible genes in the coding
region whilst the origin of light strand replication was
the most susceptible non-coding gene. The ND6, ND4
and D-loop variants were also present in the majority of
patient samples. For the normal samples, the D-loop
was the most susceptible non-coding region whilst CYT
B was the most susceptible gene in the coding region.
Interestingly, for both cohorts, COX I was the least
susceptible. COX I is one of the subunits of complex IV
of the electron transfer chain protein and is amongst the
most conserved of the proteins encoded by mtDNA
[32]. Nevertheless, the COX II and Cytochrome C
Oxidase III (COX III) genes, which also encode complex
IV subunits, were more frequently susceptible to muta-
tion than COX I in the GBM cell lines (2.26 fold) and
the normal samples (7.87 fold), respectively. CYT B is
also highly conserved [32] and the presence of variants
in this gene would explain why they were predicted to
be disease causing.
Although there was overlap between the various
regions of the mitochondrial genome that were affected,
there were regions that were specific to each cohort.
The variants detected in the origin of light strand repli-
cation, COX II and ND4L were specific to the GBM cell
lines, whereas variants specific to the normal samples
were detected in the NADH dehydrogenase 2 (ND2),
NADH dehydrogenase 3 (ND3), ATPase 6 (ATP6), ATPase
8 (ATP8) and COX III genes. This suggests that tumori-
genesis targets specific regions of the mitochondrial gen-
ome for mutagenesis. To ascertain whether our outcomes
were not biased by the cell lines and samples used, we
confirmed through PHYLIP analysis that the cell lines and
normal samples were from similar lineages and that their
respective variants were not indicative of clustered co-
horts. Furthermore, as many of the variants have not been
previously reported, it appears that we have identified a
series of mtDNA variants that are indicative of GBM,
which can be validated in a large cohort.
Mitochondrial genetics is becoming increasingly im-
portant to our understanding of aging, metabolic dis-
ease, demographic patterns of human migration and
cancer [33]. However, there is no association between
mitochondrial dysfunction and the development of
tumors in patients diagnosed with mitochondrial disease,
where a single variant or deletion is present at high
levels [34]. Moreover, no association has been effectively
described for the existence of specific variants with a
potential hotspot region for mutation [33]. Furthermore,
others have argued that the nuclear genome is primarily
responsible for the onset of tumorigenesis [35,36]. How-
ever, multiple mtDNA variants scattered throughout the
mitochondrial genome [37,38] and in specific genes,
such as ND5, are associated with the progression of
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transmitochondrial cybrids, where specific mtDNA vari-
ants have been introduced into cells with identical nuclear
backgrounds, have shown that G→A at position 13997 bp
and a frame-shift mutation at position 13885 bp caused by
the insertion of a C residue, in the ND6 gene, were in-
volved in metastasis and can affect tumor phenotype [40].
Other cybrid studies have also shown that mtDNA muta-
tions act to positively induce tumorigenesis [41-45]. How-
ever, others hypothesise that there is active selection
against unfavourable mtDNA mutations in tumor cells,
due to the monoclonal origin of tumors whilst normal
tissues are highly polyclonal in nature, thus promoting the
selection of non-mutated mtDNA [46].
There are a number of studies that do not support the
presence of mitochondrial mutations as a cause for
tumorigenesis. In 2001, Kirches et al. analysed the D-
loop of 17 paired GBM samples for mtDNA mutations,
only to observe that 7 of the 17 tumors possessed
variants [47]. The same authors later published a short
report describing the absence of any sequence variant in
10 paired astrocytoma samples [48]. Moreover, in a
study that focused on mtDNA mutations in mouse brain
tumors, no pathogenic variants were detected across the
mitochondrial genome in both induced and spontan-
eously developed tumors [49]. Seoane et al. also argued
that the maintenance of mtDNA integrity is essential in
order for tumor cells to survive increased reactive oxy-
gen species production, which is associated with tumori-
genesis [50,51]. Altogether, it remains controversial
whether mtDNA mutations arise as a cause or conse-
quence of tumorigenesis. However, our data support the
role of mtDNA as an initiator of tumorigenesis.
From our results, not only were the vast majority of
HSR-GBM1 specific variants reestablished in cells depleted
to varying degrees, but new variants were introduced as a
function of mtDNA depletion. This is highlighted by those
tumors generated from cells depleted to 20%, 3% and 0.2%
of their original copy number. Interestingly, those variants
that had been identified in the MitoMap database were
present in all or nearly all of the newly formed tumors
suggesting that there is a common core of mtDNA variants
in tumors. Furthermore, 5/6 variants that had been estab-
lished as de novo variants in the tumors have not been
previously reported. To confirm that the newly derived
variants were not indicative of clonal expansion from very
few residual variants present in the cells, we analysed the
raw data from the next generation sequencing runs for the
HSR-GBM1 cell line and were able to confirm that these
variants had not been called. Consequently, the induction
of de novo mtDNA variants appears to be essential to the
onset of tumorigenesis. Furthermore, our results reaffirm
that ND4 and ND6 are the most susceptible genes to
mutation in GBM and that GBM is likely to be a complexI disorder, which is supported by the one previous finding,
prior to next generation sequencing, that complex I along
with the D-loop is implicated in GBM [47]. Consequently,
complex I would be a pharmaceutical target for the
development of potential therapies.
Overall, the repopulation of depleted cells with mito-
chondria appears to be essential during tumorigenesis, as
recently demonstrated [52]. The accumulation of mtDNA
variants would result in a dysfunctional electron transfer
chain that promotes reduced OXPHOS output, as is the
case for GBM [53] and forces cells to adopt glycolysis,
supported by low levels of OXPHOS. As a result, mtDNA
copy number remains suppressed, which promotes the
metabolic state of aerobic glycolysis, first proposed by
Otto Warburg in 1956 [9]. This form of metabolism pro-
motes self-renewal and cellular proliferation, which is also
favoured by adult and embryonic stem cells [54-57]. How-
ever, embryonic and adult stem cells have the potential to
differentiate into mature cell types, increase their mtDNA
copy number and, consequently, switch from anaerobic
metabolism to OXPHOS as their primary method of
metabolism [52,56,58,59].Conclusion
We have identified a series of novel mtDNA variants by
screening GBM cell lines. Mutations at positions 2130 bp
within the 16 s rRNA and 5752 bp within the origin of light
strand replication were sites of frequent mutation across the
cell lines. Most of the GBM variants identified in the non-
coding regions of mtDNA were within the D-loop region,
whereas most variants in the coding portion resided within
the ND4 region. However, ND6 was determined to be the
most susceptible mtDNA region for the development of
mutation in the GBM cells, given that it contained the most
variants following normalization for the different sizes of the
mtDNA regions. These outcomes were further endorsed
by mtDNA depletion and in vivo replenishment during
tumorigenesis and analysis of patient tumor samples, which
support the hypothesis that mtDNA variants in complex I
act as initiators of GBM.Additional files
Additional file 1: Table S1. HRM primers used to screen for mtDNA variants.
Additional file 2: Supplementary Methods.
Additional file 3: Figure S1. Determining the threshold sensitivity of the Ion
Torrent PGM with HRM. (A) Mutant and wild-type recombinant plasmids
containing a 223 bp amplicon carrying the MELAS A3243G mutation were
sequenced using capillary sequencing. (B) Sensitivity levels of the Ion Torrent
to detect specific percentage of mutation generated by mixing wild-type and
mutant plasmid DNA. Confirmation of variant detection is also indicated
for HRM. (C) The mutant/wild-type specific dilutions at various known
percentages were examined by HRM and the results from the difference
curves obtained are presented. The 100% mutant plasmid DNA is set as the
baseline for comparison for this experiment.
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to confirm the presence of mtDNA variants on the GBM cell lines HK301,
SF-767 and BAH1.
Additional file 5: Table S2. Normalisation of the identified variants to
the size of the mtDNA region on which they reside to determine
susceptibility of each region to the acquisition of mutations, based on
the variant screen across all GBM cell lines. Table S3. Comparison of the
different mtDNA regions to their susceptibility to develop mutations
based on normalised data against the size of the different mtDNA
regions. Table S4. Susceptibility table for each mtDNA region, based on
the next generation sequencing results obtained from normal brain
samples, to the development of variants. The size of each mtDNA region
was normalised to allow for comparative analyses to identify the regions
most susceptible and least susceptible to mutation. Table S5. Fold
change comparison of the different susceptibility scores calculated for
each mtDNA region of normal brain samples based on the information
from Additional file 5: Table S4. Table S6. HRM analysis of HSR-GBM1
cells depleted to 50% (mtDNA50), 20% (mtDNA20) and 3% (mtDNA3) of
their original mtDNA content. They were then allowed to recover in
culture over 14 days and screened by HRM using the panel of primers for
the variants identified from the GBM cell lines in Tables 1 and 2, and
Figure 2 to determine whether they harbored the same mtDNA variants.
Table S7. HRM analysis on 22 GBM patient tumor samples screened using
the panel of primers for the variants identified from the GBM cell lines in
Tables 1, 2 and Figure 2 to identify whether these tumor samples harbor
the same mtDNA variants.
Additional file 6: Figure S3. Protein modeling of bovine complex IV of
the mitochondrial respiratory chain, with identification of the COX I
V366M mutation. (A) The catalytic centre of complex IV is represented in
its entirety with subunits COX I (purple), II (blue) and III (green). Several of
the key components are shown; heme a and a3 reside within COX I.
Heme a3 and the copper B (CuB) centre together form a bimetallic site.
Through these redox cofactors an electron transfer process occurs, which
is initiated from ferrocytochrome c transferring electrons to the copper A
(CuA) site. The cascade of electron flow occurs as follows from the CuA
centre: heme a to the heme a3 - CuB site, which binds to and reduces
molecular oxygen to water. The magnesium (Mg2+) centre functions to
maintain activity of complex IV. (B) The valine to methionine substitution
(yellow) is shown at position 366 of the COX I protein subunit, residing
within a transmembrane helical domain close to COX II and the
intermembrane space. (C) Magnified view of the V366M mutation.
Additional file 7: Figure S4. Location of the proline to threonine
(P223T) mutation in the bovine COX II protein subunit. (A) The P223T
mutation resides within a helical segment of COX II in the mitochondrial
intermembrane space. (B) Magnified observation of the same P223T
mutation.
Additional file 8: Figure S5. Phylogenetic analysis using the PHYLIP
software package to determine the evolutionary relationships between
the GBM cell lines and normal brain samples.Competing interests
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